Literature DB >> 2402117

Interleukin 6 is an autocrine growth factor for mesangial cells.

C Ruef1, K Budde, J Lacy, W Northemann, M Baumann, R B Sterzel, D L Coleman.   

Abstract

Interleukin 6 (IL-6) induces the acute phase response, differentiation of B cells, proliferation of T cells, thymocytes, hematopoietic progenitors, hybridoma and plasmacytoma cells. Monocytes, T cells, fibroblasts, epithelial and endothelial cells secrete IL-6. Since IL-6 responsive cell-types may participate in the pathogenesis of glomerular inflammation, we studied the secretion of IL-6 by rat MCs, using the IL-6 dependent hybridoma cell line B9. The results of our studies indicate that MCs secrete IL-6 with a molecular weight of 17-42 kDa and isoelectric point of 4.0 to 5.3 MC-IL-6 activity could be blocked by a polyclonal antimurine-IL-6 antibody. MC express IL-6 mRNA as determined by Northern blot. Furthermore, our data demonstrate that IL-6 acts as an autocrine growth factor for MC. Incubation of subconfluent MC with recombinant IL-6 results in a dose-dependent increase of 3H-thymidine incorporation and number of MCs. Moreover, reverse phase HPLC fractions of MC-CM containing IL-6 activity increase 3H-thymidine incorporation by MC. In addition to its possible paracrine role in mediating the immune response in the glomerulus, MC-IL-6 may also be one of the autocrine signals leading to mesangial cell proliferation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402117     DOI: 10.1038/ki.1990.193

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  51 in total

Review 1.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 2.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

3.  Altered production of IgE and IgA induced by IL-4 in peripheral blood mononuclear cells from patients with IgA nephropathy.

Authors:  N Yano; M Endoh; M Miyazaki; F Yamauchi; Y Nomoto; H Sakai
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Manidipine regulates the transcription of cytokine genes.

Authors:  M Roth; R Keul; L R Emmons; W H Hörl; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.

Authors:  S Kakumu; A Fukatsu; T Shinagawa; S Kurokawa; A Kusakabe
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

6.  Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.

Authors:  Y Maeshima; N Kashihara; T Yasuda; H Sugiyama; T Sekikawa; K Okamoto; K Kanao; Y Watanabe; Y S Kanwar; H Makino
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

7.  Phenotypic characterization of cytokine expression in patients with IgA nephropathy.

Authors:  N Yano; M Endoh; Y Nomoto; H Sakai; K Fadden; A Rifai
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

8.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

9.  Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.

Authors:  B Ryffel; B D Car; H Gunn; D Roman; P Hiestand; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

10.  A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8.

Authors:  R Ziesche; M Roth; E Papakonstantinou; M Nauck; W H Hörl; M Kashgarian; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.